Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 18/20 | 0.72 |
| ▸ | PRKDC | P78527 | 5/20 | 0.72 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 2/20 | 0.47 |
| ▸ | LDHB | P07195 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461548 | 0.88 | ATR (0.68) | ATRPRKDCATMLDHALDHB | |
| SCHEMBL2485557 | 0.84 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL23732980 | 0.83 | ATR (0.52) | ATRPRKDCATMLDHALDHB | |
| SCHEMBL2906225 | 0.82 | ATR (0.72) | ATRPRKDCATMLDHALDHB | |
| SCHEMBL11906801 | 0.82 | ATR (0.72) | ATRPRKDCATM | |
| SCHEMBL11908982 | 0.82 | ATR (0.74) | ATRPRKDCATMLDHALDHB | |
| SCHEMBL11907341 | 0.81 | ATR (0.53) | ATRPRKDCATM | |
| SCHEMBL318797 | 0.80 | ATR (0.68) | ATRPRKDCATM | |
| SCHEMBL28174453 | 0.79 | ATR (0.56) | ATRPRKDCATMLDHALDHB | |
| SCHEMBL11907392 | 0.79 | ATR (0.74) | ATRPRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885PRKDC 9/4885ATM 143/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885PRKDC 9/4885ATM 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.